What is it about?
This study provides the first validation of COMPASS 31 for diabetic cardiovascular autonomic neuropathy (CAN). Rather unexpectedly, Compass 31 also showed an acceptable diagnostic performance for diabetic polyneuropathy.
Featured Image
Why is it important?
Current guidelines recommend assessing autonomic symptoms in people with diabetes. However, the questionnaires validated to this end are rare or tricky to use. COMPASS 31 is reliable and easy to use questionnaire for autonomic symptoms.
Perspectives
COMPASS 31 is open to a possible clinical utilization as a screening tool for CAN
Prof Vincenza Spallone
University of Rome Tor Vergata
Read the Original
This page is a summary of: Validation of the Composite Autonomic Symptom Score 31 (COMPASS 31) for the assessment of symptoms of autonomic neuropathy in people with diabetes, Diabetic Medicine, January 2017, Wiley,
DOI: 10.1111/dme.13310.
You can read the full text:
Contributors
The following have contributed to this page
